31
Jan
2023
Rebounding From a Setback With a Transformative Partnership
One of the well-known rituals at many companies is the holiday party. It’s a way to unwind after a long and demanding year and get to know our colleagues better. The January gathering was extra special at Spero Therapeutics. This was our first in-person holiday celebration in three years. We gathered at a hotel in Cambridge, not far from the... Read More
13
Oct
2022
The Next Pandemic May Be Bacterial or Fungal. What Are We Doing to Prepare?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Feb
2021
Comprehensive Policy for Infection: There Has Never Been a Better Time
The suffering from COVID-19 can be measured in multiple, sobering ways: Life expectancy in the US has fallen by a full year, according to the CDC. The economic cost – measured in reduced gross domestic product, premature death, and long-term disability – has been estimated at $16 trillion by economists David Cutler and Larry Summers at Harvard University. This week,... Read More
19
Oct
2020
Getting Ready for the Next Pandemic With a Comprehensive Response
The progress in developing therapies and vaccines for COVID-19 has been extraordinary, and has received extraordinary attention. But there’s another good news story beginning to emerge, about our widening array of defenses against bacterial infectious disease. On the clinical front in the past month, developers have announced positive Phase III trials in difficult diseases that have been marked with prior... Read More
13
Jul
2020
Playing the Long Game for Antibiotic R&D
This week’s unveiling of the AMR Action Fund, a $1 billion public/private consortium anchored by 23 pharmaceutical companies to support the development and commercialization of antibiotics, is a welcome development in the fight against antimicrobial resistant infections. The money is important, but it was very encouraging to see the leadership of major pharmaceutical companies — Pfizer, Merck, and Eli... Read More
1
Apr
2020
Thinking Ahead: Building a Broad Arsenal Against Infectious Disease
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.